(NewsDirect)
By Rachael Green, Benzinga
Earlier this month, Pressure BioSciences, Inc. (OTCQB: PBIO) announced potentially ground-breaking results from a consumer focus grouptesting a THC oral spray developed using the company’s innovativeUltraShear™ Technology nanoemulsification platform. The oral sprayboasted strong potency and extremely fast absorption that could put iton track to become a best-in-class cannabis product in terms of speedto effects, stability, and bioavailability. The THC oral spray testedin this consumer focus group is being developed in partnership withCalifornia-based cannabis manufacturer, Crème De Canna.
The news comes on theheels of the company’s December announcement of its first commercial shipment of a CBD oral spray manufactured withthe same UltraShear technology. The $75,000 shipment to Safer Medicalof Montana is the first of many shipments the company expects to maketo distributors of CBD products throughout the U.S. during 2023. Inrecent press releases, PBIO has stated that CBD products manufacturedusing its patented UltraShear platform could potentially yield manymillions in revenue before the end of its 2023 fiscal year.
Slow And Inconsistent THC Absorption RemainsA Key Challenge for Cannabis Manufacturers
Because cannabinoids,like the well-known THC and CBD, are oil-soluble rather thanwater-soluble, the human body struggles to absorb them efficiently. Asa consequence, much of the active ingredient in edible cannabisproducts is absorbed slowly, intermittently, or hardly at all.
In one review ofcannabis research, only 4% to 12% of THC was absorbed by the body whentaken orally. Not only does that mean that the majority of the THC inan edible ends up getting wasted, but the variation in bioavailabilitybetween 4% and 12% is highly significant. A consumer eating the sameedible product from the same manufacturer with the same dose mightabsorb just 4% one day but 12% the next day, leading to very differentresults.
Thismakes it incredibly difficult for manufacturers to achieve precisedosing and effects in their edibles. It also increases productioncosts since they often need to include more than the minimum effectivedose to compensate for the fact that most of the active ingredientswon’t be absorbed.
In addition to inefficient and inconsistent cannabinoidabsorption, another challenge in the edible cannabis industry isabsorption time. It is estimated to take anywhere from 30minutes to two hours from the time a consumer ingests anedible to the time they start to feel its first effects, and then upto four hours to achieve peak effects.
“Impatient consumers may repeatedly consumetheir edibles, only to be unhappily overdosed shortly thereafter,”explained PBI’s Director of Sales and Marketing, John Hollister in a statement on the consumer testing results. For patients using cannabis as atreatment for pain, anxiety, or depression, that delayed response alsomeans edible cannabis is often unable to provide the instant reliefthey need.
Whilesmoking or vaping comes with a higher bioavailability of around 30%and a faster response time of seconds or minutes, the respiratoryhealth consequences make it a less-than-ideal option, especially forregular use.
PBI’s UltraShearNanoemulsion Technology Could Be A Breakthrough In Achieving PrecisionDosing for THC, CBD, and Other Products
Consumers in the focus group reported that thefirst effects could be felt less than 10 minutes after initially usingthe innovative UltraShear processed THC oral spray, with manyreporting noticeable effects within 1-5 minutes. Peak effects wereachieved between 15-60 minutes after taking the dose. The results ofthis initial focus group could be a game-changer for an industrythat’s been struggling with the challenges around consistent dosingand effective non-inhalation absorption.
“This testing has provided dramaticconsumer-level validation in the cannabis market for our UltraShearnanoemulsion capabilities and for its expected market-changingimpact,” said Mr. Hollister.
The UltraShear technology used to make the oralspray is PBI’s patented pressure-based platform that’s capable ofcreating what the company describes as the “best-in-class”nanoemulsions worldwide. In the cannabis nanoemulsion, the oil dropscontaining the CBD or THC molecules are sheared down to a nanosize sosmall that they are effectively water-soluble. This makes for asignificantly more easily absorbed product that can be more preciselyand accurately dosed.
For consumers, that means more immediate and consistent effectsevery time they use an UltraShear processed oral spray or othermechanisms for ingestion. For manufacturers, that improvedbioavailability means smaller amounts of THC or CBD are required toachieve an effective dose since the less active ingredient is gettingwasted - thus saving the manufacturer money.
“It provides aneasy-to-use, reliable, and healthy alternative dosing format, withnearly immediate onset and a consistent experience associated withinhaling, but without the respiratory health risks associated withsmoking and vaping. It also eliminates the frustrating delayedeffects, imprecision, and frequent overdosing associated withedibles,” said Crème De Canna President, Jonathan Kolodinski.
This article wasoriginally published on Benzinga here .
PressureBioSciences, Inc. (OTCQB:PBIO) is a leader in the development and saleof innovative, broadly enabling, pressure-based solutions for theworldwide life sciences and other industries. Our products are basedon the unique properties of both constant (i.e., static) andalternating (i.e., pressure cycling technology, or PCT) hydrostaticpressure. PCT is a patented enabling technology platform that usesalternating cycles of hydrostatic pressure between ambient andultra-high levels to control bio-molecular interactions safely andreproducibly (e.g., cell lysis, biomolecule extraction). Our primaryfocus is in the development of PCT-based products for biomarker andtarget discovery, drug design and development, biotherapeuticscharacterization and quality control, soil & plant biology,forensics, and counter-bioterror applications. Additionally, major newmarket opportunities have emerged in the use of our pressure-basedtechnologies in the following areas: (1) the use of our recentlyacquired, patented technology from BaroFold, Inc. (the"BaroFold" technology) to allow entry into the bio-pharmacontract services sector, and (2) the use of our recently-patented,scalable, high-efficiency, pressure-based Ultra Shear Technology("UST") platform to (i) create stable nanoemulsions ofotherwise immiscible fluids (e.g., oils and water) and to (ii) preparehigher quality, homogenized, extended shelf-life or room temperaturestable low-acid liquid foods that cannot be effectively preservedusing existing non-thermal technologies.
This pressrelease contains forward-looking statements. These statements relateto future events or our future financial performance and involve knownand unknown risks, uncertainties and other factors that may cause ouror our industry's actual results, levels of activity, performance,or achievements to be materially different from any future results,levels of activity, performance or achievements expressed, implied, orinferred by these forward-looking statements. In some cases, you canidentify forward-looking statements by terminology such as"may," "will," "should," "could,""would," "expects," "plans,""intends," "anticipates," "believes,"estimates," "predicts," "projects,""potential" or "continue" or the negative of suchterms and other comparable terminology. These statements are onlypredictions based on our current expectations and projections aboutfuture events. You should not place undue reliance on thesestatements. In evaluating these statements, you should specificallyconsider various factors. Actual events or results may differmaterially. These and other factors may cause our actual results todiffer materially from any forward-looking statement. These risks,uncertainties, and other factors include, but are not limited to, therisks and uncertainties discussed under the heading "RiskFactors" in the Company's Annual Report on Form 10-K for theyear ended December 31, 2021, and other reports filed by the Companyfrom time to time with the SEC. The Company undertakes no obligationto update any of the information included in this release, except asotherwise required by law.
This post contains sponsoredadvertising content. This content is for informational purposes onlyand is not intended to be investing advice.
ContactDetails
Ken Micciche: Director, BusinessDevelopment
kmicciche@pressurebiosciences.com
CompanyWebsite
https://www.pressurebiosciences.com/
Copyright (c) 2023 TheNewswire - All rights reserved.